Not exact matches
«Our discovery
of these mutations is a first step in developing a genetics - based system
for classifying endometriosis so that clinicians can sort out which
forms of the disorder may need more
aggressive treatment and which may not,» says Ie - Ming Shih, M.D., Ph.D., the Richard W. TeLinde Distinguished Professor in the Department
of Gynecology & Obstetrics at the Johns Hopkins University School
of Medicine and co-director
of the
Breast and Ovarian
Cancer Program at the Johns Hopkins Kimmel
Cancer Center.
«This study
forms the basis
for future research in patients with
breast cancer and offers hope
for targeted therapy
for patients with
aggressive triple - negative inflammatory
breast cancer,» said lead researcher Mateusz Opyrchal, M.D., Ph.D., Assistant Professor
of Oncology at RPCI.
«The research showed that the
aggressive form of basal
breast cancer cells may be dependent on PLK4
for survival and that depleting it induced cell death,» says Dr. Mak.
This provides a potential target
for treating triple negative
breast cancer, the most
aggressive form of the disease.
For years, scientists have observed that tumor cells from certain
breast cancer patients with
aggressive forms of the disease contained low levels
of mitochondrial DNA.
Researchers led by Dr. Debra Auguste, associate professor, biomedical engineering, in the Grove School
of Engineering at The City College
of New York, have identified a molecule that could lead to developing treatment
for one
of the most
aggressive forms of breast cancer.
My honours project was centred upon exploring mechanisms that allow
for the progression
of Inflammatory
Breast Cancer, a highly rare and aggressive form of advanced breast cancer, and whether we could target these previously unknown mechanisms with novel therape
Breast Cancer, a highly rare and aggressive form of advanced breast cancer, and whether we could target these previously unknown mechanisms with novel therape
Cancer, a highly rare and
aggressive form of advanced
breast cancer, and whether we could target these previously unknown mechanisms with novel therape
breast cancer, and whether we could target these previously unknown mechanisms with novel therape
cancer, and whether we could target these previously unknown mechanisms with novel therapeutics.
This model should be a powerful tool
for testing therapies
for aggressive ER +
breast cancers and
for studying luminal
cancers — the most prevalent and deadliest
forms of breast cancer.
Research led by Dr. Carlos Arteaga, Director
of the Harold C. Simmons Comprehensive
Cancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast c
Cancer Center, has identified potential targets
for treatment
of triple negative
breast cancer, the most aggressive form of breast c
cancer, the most
aggressive form of breast cancercancer.
Many women are «triple negative» No one yet knows precisely why, but African - American women are roughly twice as likely as white women to have triple - negative
breast cancer — so called because tumor cells in this particularly
aggressive form of the disease test negative
for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER - 2).